Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia (UPCI 13-066)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01960387
Recruitment Status : Terminated (lack of accrual)
First Posted : October 10, 2013
Results First Posted : August 2, 2016
Last Update Posted : August 2, 2016
Sponsor:
Information provided by (Responsible Party):
Michael Boyiadzis, University of Pittsburgh

Brief Summary:
The combination of clofarabine and cytarabine is an effective and reasonably well-tolerated treatment regimen in patients with either relapsed/refractory or newly diagnosed AML. For this prospective study, we propose the use of clofarabine and cytarabine for second course induction therapy for patients with persistent AML after treatment with an anthracycline and cytarabine.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Drug: Clofarabine Drug: Cytarabine Phase 2

Detailed Description:

The primary objective of this prospective study is to evaluate the efficacy (i.e., complete response rate) of clofarabine and cytarabine as second course therapy for the treatment of AML. The secondary objectives are to assess the treatment-related toxicities, to determine the overall and relapse-free survival for patients with AML who are treated with this regimen, and to evaluate potential factors that are predictive of response.

The investigational nature and objective of this study, the procedures involved and their associated risks, potential benefits, and potential alternative therapies will be explained to the patient, and a signed informed consent document will be obtained. Once consented, eligible patients will be treated by the acute leukemia service on the University of Pittsburgh Cancer Institute inpatient unit.

Prior to the start of chemotherapy, patients will receive dexamethasone and ondansetron as pre-medication. Clofarabine will then be administered as intravenous infusion on days 1 through 5. Patients will be monitored closely with vital signs. Cytarabine will then be given as intravenous infusion, starting 3 (maximum of 4) hours after the completion of clofarabine administration on days 1 through 5.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Clofarabine and Cytarabine for Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Persistent Disease After Treatment With an Anthracycline and Cytarabine
Study Start Date : October 2013
Actual Primary Completion Date : March 2015
Actual Study Completion Date : March 2015


Arm Intervention/treatment
Experimental: Clofarabine and Cytarabine
Clofarabine will be administered as a 1-hour (range: 1 hour minimum to 2 hours maximum) intravenous infusion at a dose of 40mg/m2 daily on days 1 through 5. Cytarabine at a dose of 1g/m2 daily will then be given as a 2-hour intravenous infusion, starting 3 hours after the completion of clofarabine administration on days 1 through 5.
Drug: Clofarabine
Clofarabine will be administered as a 1-hour (range: 1 hour minimum to 2 hours maximum) intravenous infusion at a dose of 40mg/m2 daily on days 1 through 5.
Other Names:
  • Clolar
  • antimetabolite
  • Purine nucleoside analog

Drug: Cytarabine
Cytarabine at a dose of 1g/m2 daily will be given as a 2-hour intravenous infusion, starting 3 hours after the completion of clofarabine administration on days 1 through 5.
Other Names:
  • Cytosine arabinoside
  • antimetabolite
  • Pyrimidine analog




Primary Outcome Measures :
  1. Complete Clinical Response [ Time Frame: Between 14 and 28 days from start of study treatment ]
    Number of patients with newly diagnosed Acute Myeloid Leukemia who achieved Complete Response to therapy as determined by bone marrow biopsy evaluation. A CR designation required that the patient achieved a morphologic leukemia-free state and an absolute neutrophil count greater than or equal to 1.0 x 10^9/l, a platelet count greater than or equal to 100 x 10^9/l, and no evidence of extramedullary disease.


Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: Up to 24 months ]
    Number of months of survival for newly diagnosed Acute Myeloid Leukemia patients treated with Clofarabine (40mg/m^2/Day) + Cytarabine (1g/m^2/Day).

  2. Relapse Free Survival [ Time Frame: Up to 24 months ]
    Number of months of relapse free survival for newly diagnosed Acute Myeloid Leukemia patients treated with Clofarabine (40mg/m^2/Day) + Cytarabine (1g/m^2/Day).

  3. Predictive Factors for Response to Treatment. [ Time Frame: Up to 1 year ]
    Evaluation of potential factors that are predictive of clinical response in newly diagnosed Acute Myeloid Leukemia patients treated with Clofarabine (40mg/m^2/Day) + Cytarabine (1g/m^2/Day).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with newly diagnosed AML based on the World Health Organization classification who have persistent disease after their first course treatment with an anthracycline and cytarabine
  2. Able to understand and have the ability to provide written informed consent
  3. Patients over 18 years of age
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  5. Left ventricular ejection fraction (LVEF) ≥ 50%
  6. Negative urine pregnancy test for all females
  7. All subjects must agree to use an effective method of contraception while receiving the study drugs

Exclusion Criteria:

  1. Diagnosis of acute promyelocytic leukemia
  2. Relapsed AML
  3. Prior use of clofarabine
  4. Previous allogeneic or autologous hematopoietic cell transplantation
  5. Impaired liver function (serum total bilirubin > 2.0 mg/dL, alanine aminotransferase and aspartate aminotransferase ≥ 4 x the upper limit of normal)
  6. Impaired renal function (serum creatinine ≥ 2.0 mg/dL)
  7. Uncontrolled or life-threatening infection that is not responding to antimicrobial therapy
  8. History of a psychiatric disorder which may compromise compliance with the protocol or which does not allow for appropriate informed consent
  9. Concurrent active malignancy; exceptions include patients who have been disease free for 5 years, patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, or patients with another malignancy that is indolent or definitively treated
  10. Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory or cardiac disease)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01960387


Locations
Layout table for location information
United States, Pennsylvania
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 15232
Sponsors and Collaborators
University of Pittsburgh
Investigators
Layout table for investigator information
Principal Investigator: Michael Boyiadzis, M.D., M.H.Sc University of Pittsburgh
Layout table for additonal information
Responsible Party: Michael Boyiadzis, Principal Investigator, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT01960387    
Other Study ID Numbers: UPCI 13-066
First Posted: October 10, 2013    Key Record Dates
Results First Posted: August 2, 2016
Last Update Posted: August 2, 2016
Last Verified: June 2016
Keywords provided by Michael Boyiadzis, University of Pittsburgh:
AML
clofarabine
cytarabine
persistent AML
induction therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms
Cytarabine
Clofarabine
Antimetabolites
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs